scispace - formally typeset
F

Federico Argüelles-Arias

Researcher at University of Seville

Publications -  91
Citations -  1582

Federico Argüelles-Arias is an academic researcher from University of Seville. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 18, co-authored 73 publications receiving 1049 citations. Previous affiliations of Federico Argüelles-Arias include Telefónica.

Papers
More filters
Journal ArticleDOI

Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects

Belén Begines, +6 more
- 19 Jul 2020 - 
TL;DR: A summary of the state-of-the-art panorama of polymeric nanoparticles as drug-delivery systems has been conducted, focusing mainly on those applications in which the corresponding disease involves an important morbidity, a considerable reduction in the life quality of patients—or even a high mortality.
Journal ArticleDOI

The value of capsule endoscopy in pediatric patients with a suspicion of Crohn's disease.

Federico Argüelles-Arias, +7 more
- 28 Sep 2004 - 
TL;DR: CE appears to be a very useful diagnostic tool in children with Crohn's disease, and is safe in pediatric patients over 12 years of age.
Journal ArticleDOI

Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease

María José Casanova, +59 more
- 04 Dec 2017 - 
TL;DR: The prevalence of malnutrition in inflammatory bowel disease patients was high and some predictive factors of malnutrition were identified, including history of abdominal surgery, active disease and avoidance of some foods during flares were associated with higher risk of malnutrition.
Journal ArticleDOI

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.

María José Casanova, +82 more
- 01 Jan 2017 - 
TL;DR: The incidence rate of inflammatory bowel disease relapse after anti-TNF discontinuation is relevant and some predictive factors of relapse afterAnti-tumor necrosis factor drugs withdrawal have been identified and treatment with the same anti- TNF drug was effective and safe.
Journal ArticleDOI

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.

Carlos Taxonera, +21 more
- 01 Aug 2017 - 
TL;DR: In this real-life cohort of patients with UC, golimumab therapy was effective for inducing and maintaining clinical response and was also effective in anti-TNF–experienced patients.